NCT05807269 Prevention and Rehabilitation of Stroke in Uganda
| NCT ID | NCT05807269 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Karolinska Institutet |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-11-01 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-11-01 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke is increasing in low-income countries in Africa, and knowledge is lacking on risk factors and how to prevent stroke as well as how to best use the resources for rehabilitation after stroke which are very limited. Knowledge generation within this area is therefore urgently needed. This collaboration between the research group HELD (Health and Everyday Life among people with neurological Disorders), Karolinska Institutet (KI) and the research surveillant site Africa Medical and Behavioral Sciences Organization (AMBSO) population health surveillance (PHS), will create substantial research opportunities to develop and improve prevention and rehabilitation for stroke, which is in line with the sustainable development goals to reduce the prevalence and mortality rates due to NCDs. AMBSO is collecting data from 17 000 households on many potential risk factors for stroke. Questions about stroke primary and secondary prevention of stroke and impact of stroke or need of rehabilitation could be added to the existing questionnaires such as the validated Ugandan version of the Stroke Impact Scale. This is intended to fulfill the aim of the network which is to increase the knowledge of occurrence and consequences of NCDs with a specific focus on stroke, which will be valuable for the development of preventive healthcare policy documents and guidelines for appropriate prevention strategies and rehabilitation interventions. Research questions in relation to NCDs with focus on stroke prevention and rehabilitation: * How many cases (prevalence) are reported in the targeted study sites and what is the mortality rate (incidence) that can specifically relate to stroke? * How does stroke and other NCDs affect and impact the quality of life for persons living in Uganda? * Which factors impact the recovery process after stroke? * What sort of rehabilitation is needed in the study areas for persons affected by stroke? In addition, risk factors of stroke such as diabetes and hypertension will be mapped.
Eligibility Criteria
Inclusion Criteria: * Stroke * Risk factors for stroke: hypertension, diabetes, HIV, malaria, physical inactivity, obesity Exclusion Criteria: * Not having had stroke and/or having no risk factor for stroke
Contact & Investigator
Gunilla Eriksson, PhD
PRINCIPAL INVESTIGATOR
Karolinska Institutet
Frequently Asked Questions
Who can join the NCT05807269 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05807269 currently recruiting?
Yes, NCT05807269 is actively recruiting participants. Contact the research team at gunilla.eriksson@ki.se for enrollment information.
Where is the NCT05807269 trial being conducted?
This trial is being conducted at Hoima, Uganda, Kampala, Uganda.
Who is sponsoring the NCT05807269 clinical trial?
NCT05807269 is sponsored by Karolinska Institutet. The principal investigator is Gunilla Eriksson, PhD at Karolinska Institutet. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.